Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Research

Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer

Authors: Xingzhi Li, Ziji Liang, Jiexin Pan, Meng Zhang, Jinli Liu, Rong Hu, Caiyan Liao

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

The sialic acid binding Ig like lectin 15 (Siglec-15) was previously identified as tumor immune suppressor gene in some human cancers with elusive molecular mechanism to be elucidated. The continuous focus on both clinical and basic biology of bladder cancer leads us to characterize aberrant abundance of BACH1-IT2 associating with stabilization of Siglec-15, which eventually contributes to local immune suppressive microenvironment and therefore tumor advance. This effect was evidently mediated by miR-4786-5p. BACH1-IT2 functions in this scenario as microRNA sponge, and competitively conceals miR-4786 and up-regulates cancer cell surface Siglec-15. The BACH1-IT2-miR-4786-Siglec-15 axis significantly influences activation of immune cell co-culture. In summary, our data highlights the critical involvements of BACH1-IT2 and miR-4786 in immune evasion in bladder cancer, which hints the potential for both therapeutic and prognostic exploitation.
Appendix
Available only for authorised users
Literature
4.
go back to reference Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25.CrossRefPubMedPubMedCentral Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25.CrossRefPubMedPubMedCentral
5.
go back to reference Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.CrossRefPubMed Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.CrossRefPubMed
7.
go back to reference Manfredi S, Drouillard A. Immune-checkpoint inhibition for digestive cancers. Lancet Oncol. 2017;18(5):561–2.CrossRefPubMed Manfredi S, Drouillard A. Immune-checkpoint inhibition for digestive cancers. Lancet Oncol. 2017;18(5):561–2.CrossRefPubMed
8.
go back to reference Souquet PJ, Couraud S. Immune checkpoint inhibitors: a game changer for metastatic non-small-cell lung cancer. Lancet Oncol. 2019;20(10):1334–5.CrossRefPubMed Souquet PJ, Couraud S. Immune checkpoint inhibitors: a game changer for metastatic non-small-cell lung cancer. Lancet Oncol. 2019;20(10):1334–5.CrossRefPubMed
9.
go back to reference Angata T, Tabuchi Y, Nakamura K, Nakamura M. Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. Glycobiology. 2007;17(8):838–46.CrossRefPubMed Angata T, Tabuchi Y, Nakamura K, Nakamura M. Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. Glycobiology. 2007;17(8):838–46.CrossRefPubMed
10.
go back to reference Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25(4):656–66.CrossRefPubMedPubMedCentral Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25(4):656–66.CrossRefPubMedPubMedCentral
11.
go back to reference Poh A. Siglec-15: An attractive immunotherapy target. Cancer Discov. 2020;10(1):7–8. Poh A. Siglec-15: An attractive immunotherapy target. Cancer Discov. 2020;10(1):7–8.
12.
go back to reference Liu Y, Li X, Zhang C, Zhang H, Huang Y. LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma. Cancer Sci. 2020;111(10):3693–704.CrossRefPubMedPubMedCentral Liu Y, Li X, Zhang C, Zhang H, Huang Y. LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma. Cancer Sci. 2020;111(10):3693–704.CrossRefPubMedPubMedCentral
13.
go back to reference Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272–83.CrossRefPubMed Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272–83.CrossRefPubMed
14.
go back to reference Quirino MWL, Pereira MC, Deodato de Souza MF, Pitta IDR, Da Silva Filho AF, Albuquerque MSS, et al. Immunopositivity for Siglec-15 in gastric cancer and its association with clinical and pathological parameters. Eur J Histochem. 2021;65(1):3174.CrossRefPubMedPubMedCentral Quirino MWL, Pereira MC, Deodato de Souza MF, Pitta IDR, Da Silva Filho AF, Albuquerque MSS, et al. Immunopositivity for Siglec-15 in gastric cancer and its association with clinical and pathological parameters. Eur J Histochem. 2021;65(1):3174.CrossRefPubMedPubMedCentral
15.
go back to reference Zheng B, Song K, Sun L, Gao Y, Qu Y, Ren C, et al. Siglec-15-induced autophagy promotes invasion and metastasis of human osteosarcoma cells by activating the epithelial-mesenchymal transition and Beclin-1/ATG14 pathway. Cell Biosci. 2022;12(1):109.CrossRefPubMedPubMedCentral Zheng B, Song K, Sun L, Gao Y, Qu Y, Ren C, et al. Siglec-15-induced autophagy promotes invasion and metastasis of human osteosarcoma cells by activating the epithelial-mesenchymal transition and Beclin-1/ATG14 pathway. Cell Biosci. 2022;12(1):109.CrossRefPubMedPubMedCentral
16.
go back to reference Chen Q, Chen B, Wang C, Hu L, Wu Q, Zhu Y, et al. Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma. Front Immunol. 2023;14:1159085.CrossRefPubMedPubMedCentral Chen Q, Chen B, Wang C, Hu L, Wu Q, Zhu Y, et al. Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma. Front Immunol. 2023;14:1159085.CrossRefPubMedPubMedCentral
17.
go back to reference Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet. 2016;17(12):719–32.CrossRefPubMed Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet. 2016;17(12):719–32.CrossRefPubMed
18.
go back to reference Zhu R, Zhao W, Fan F, Tang L, Liu J, Luo T, et al. A 3-miRNA signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia. Oncotarget. 2017;8(24):38902–13.CrossRefPubMedPubMedCentral Zhu R, Zhao W, Fan F, Tang L, Liu J, Luo T, et al. A 3-miRNA signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia. Oncotarget. 2017;8(24):38902–13.CrossRefPubMedPubMedCentral
19.
go back to reference He RQ, Wei QJ, Tang RX, Chen WJ, Yang X, Peng ZG, et al. Prediction of clinical outcome and survival in soft-tissue sarcoma using a ten-lncRNA signature. Oncotarget. 2017;8(46):80336–47.CrossRefPubMedPubMedCentral He RQ, Wei QJ, Tang RX, Chen WJ, Yang X, Peng ZG, et al. Prediction of clinical outcome and survival in soft-tissue sarcoma using a ten-lncRNA signature. Oncotarget. 2017;8(46):80336–47.CrossRefPubMedPubMedCentral
Metadata
Title
Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer
Authors
Xingzhi Li
Ziji Liang
Jiexin Pan
Meng Zhang
Jinli Liu
Rong Hu
Caiyan Liao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12061-8

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine